{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:48Z","timestamp":1792264968310,"version":"4.4.0"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2023]]},"DOI":"10.4103\/1673-5374.360289","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T07:45:10Z","timestamp":1667288710000},"page":"1472","source":"Crossref","is-referenced-by-count":68,"title":["Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies"],"prefix":"10.4103","volume":"18","author":[{"given":"Anamaria","family":"Jurcau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CarolinaMaria","family":"Jurcau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.360289-1","doi-asserted-by":"crossref","unstructured":"Adebayo M, Singh S, Singh AP, Dasgupta S (2021) Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis. FASEB J 35:e21620.","DOI":"10.1096\/fj.202100067R"},{"key":"key-10.4103\/1673-5374.360289-2","doi-asserted-by":"crossref","unstructured":"Aladdin A, Kir\u00e1ly E, Boto P, Regdon Z, Tar K (2019) Juvenile Huntington\u2019s disease skin fibroblasts respond with elevated parkin levels and increased proteasome activity as a potential mechanism to counterbalance the pathological consequences of mutant huntingtin protein. Int J Mol Sci 20:5338.","DOI":"10.3390\/ijms20215338"},{"key":"key-10.4103\/1673-5374.360289-3","doi-asserted-by":"crossref","unstructured":"Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Y\u00e9benez JG, Boesiger P, Weindl A, Maguire RP (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain 119:2085-2095.","DOI":"10.1093\/brain\/119.6.2085"},{"key":"key-10.4103\/1673-5374.360289-4","doi-asserted-by":"crossref","unstructured":"Askeland G, Dosoudilova Z, Rodinova M, Klempir J, Liskova I, Ku\u015bnierczyk A, Bj\u00f8r\u00e5s M, Nesse G, Klungland A, Hansikova H, Eide L (2018) Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington\u2019s disease patients. Sci Rep 8:9817.","DOI":"10.1038\/s41598-018-27985-y"},{"key":"key-10.4103\/1673-5374.360289-5","doi-asserted-by":"crossref","unstructured":"Bae BI, Hara MR, Cascio MB, Wellington CL, Hayden MR, Ross CA, Ha HC, Li XJ, Snyder SH, Sawa A (2006) Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci U S A 103:3405-3409.","DOI":"10.1073\/pnas.0511316103"},{"key":"key-10.4103\/1673-5374.360289-6","doi-asserted-by":"crossref","unstructured":"Bausewein T, Mills DJ, Langer JD, Nitschke B, Nussberger S, K\u00fchlbrandt W (2017) Cryo-EM structure of the TOM core complex from Neurospora crassa. Cell 170:693-700.","DOI":"10.1016\/j.cell.2017.07.012"},{"key":"key-10.4103\/1673-5374.360289-7","doi-asserted-by":"crossref","unstructured":"Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, D\u00e9glon N, Brouillet E (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652-1663.","DOI":"10.1091\/mbc.e05-07-0607"},{"key":"key-10.4103\/1673-5374.360289-8","doi-asserted-by":"crossref","unstructured":"Braithwaite SP, Paul S, Nairn AC, Lombroso PJ (2006) Synaptic plasticity: one STEP at a time. Trends Neurosci 29:452-458.","DOI":"10.1016\/j.tins.2006.06.007"},{"key":"key-10.4103\/1673-5374.360289-9","doi-asserted-by":"crossref","unstructured":"Cardinali DP (2019) Melatonin: clinical perspectives in neurodegeneration. Front Endocrinol 10:480.","DOI":"10.3389\/fendo.2019.00480"},{"key":"key-10.4103\/1673-5374.360289-10","doi-asserted-by":"crossref","unstructured":"Carmo C, Naia L, Lopes C, Rego AC (2018) Mitochondrial dysfunction in Huntington\u2019s disease. Adv Exp Med Biol 1049:59-83.","DOI":"10.1007\/978-3-319-71779-1_3"},{"key":"key-10.4103\/1673-5374.360289-11","doi-asserted-by":"crossref","unstructured":"Chen CM, Wu YR, Chang KH (2017) Altered Aconitase 2 activity in Huntington\u2019s disease peripheral blood cells and mouse model striatum. Int J Mol Sci 18:2480.","DOI":"10.3390\/ijms18112480"},{"key":"key-10.4103\/1673-5374.360289-12","doi-asserted-by":"crossref","unstructured":"Choi SA, Kim SJ, Chung KC (2006) Huntingtin-interacting protein 1-mediated neuronal cell death occurs through intrinsic apoptotic pathways and mitochondrial alterations. FEBS Lett 580:5275-5282.","DOI":"10.1016\/j.febslet.2006.08.076"},{"key":"key-10.4103\/1673-5374.360289-13","doi-asserted-by":"crossref","unstructured":"Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JCD, Jansson EKH, Eckert GP, Pichler BJ, Bordet T, Pruss RM, Riess O, Nguyen HP (2015) Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Brain 138:3632-3653.","DOI":"10.1093\/brain\/awv290"},{"key":"key-10.4103\/1673-5374.360289-14","doi-asserted-by":"crossref","unstructured":"Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59-69.","DOI":"10.1016\/j.cell.2006.09.015"},{"key":"key-10.4103\/1673-5374.360289-15","doi-asserted-by":"crossref","unstructured":"Deitmer JW, Theparambil SM, Ruminot I, Noor SI, Becker HM (2019) Energy dynamics in the brain: contributions of astrocytes to metabolism and pH homeostasis. Front Neurosci 13:1301.","DOI":"10.3389\/fnins.2019.01301"},{"key":"key-10.4103\/1673-5374.360289-16","doi-asserted-by":"crossref","unstructured":"Delprat B, Crouzier L, Su TP, Maurice T (2020) At the crossing of ER stress and MAMs: a key role of sigma-1 receptor? Adv Exp Med Biol 1131:699-718.","DOI":"10.1007\/978-3-030-12457-1_28"},{"key":"key-10.4103\/1673-5374.360289-17","doi-asserted-by":"crossref","unstructured":"Di Rita A, Maiorino T, Bruqi K, Volpicelli F, Bellenchi GC, Strappazzon F (2020) miR-218 inhibits mitochondrial clearance by targeting PRKN E3 ubiquitin ligase. Int J Mol Sci 21:355.","DOI":"10.3390\/ijms21010355"},{"key":"key-10.4103\/1673-5374.360289-18","doi-asserted-by":"crossref","unstructured":"D\u00edez-Planelles C, S\u00e1nchez-Lozano P, Crespo MC, Gil-Zamorano J, Ribacoba R, Gonz\u00e1lez N, Su\u00e1rez E, Mart\u00ednez-Descals A, Mart\u00ednez-Camblor P, \u00c1lvarez V, Mart\u00edn-Hern\u00e1ndez R, Huerta-Ru\u00edz I, Gonz\u00e1lez-Garc\u00eda I, Cosgaya JM, Visioli F, D\u00e1valos A, Iglesias-Guti\u00e9rrez E, Tom\u00e1s-Zapico C (2016) Circulating microRNAs in Huntington\u2019s disease: emerging mediators in metabolic impairment. Pharmacol Res 108:102-110.","DOI":"10.1016\/j.phrs.2016.05.005"},{"key":"key-10.4103\/1673-5374.360289-19","doi-asserted-by":"crossref","unstructured":"Ding XW, Robinson M, Li R, Aldhowayan H, Geetha T, Babu JR (2021) Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in diabetes mellitus and Alzheimer\u2019s disease. Pharmacol Res 171:105783.","DOI":"10.1016\/j.phrs.2021.105783"},{"key":"key-10.4103\/1673-5374.360289-20","doi-asserted-by":"crossref","unstructured":"Dubois C, Kong G, Tran H, Li S, Pang TY, Hannan AJ, Renoir T (2021) Small non-coding RNAs are dysregulated in Huntington\u2019s disease transgenic mice independently of the therapeutic effects of an environmental intervention. Mol Neurobiol 58:3308-3318.","DOI":"10.1007\/s12035-021-02342-9"},{"key":"key-10.4103\/1673-5374.360289-21","doi-asserted-by":"crossref","unstructured":"Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A, Madonna M, Filosa S, Calogero A, Maglione V, Crispi S, Di Pardo A (2019) Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington\u2019s disease. Hum Mol Genet 28:4012-4021.","DOI":"10.1093\/hmg\/ddz247"},{"key":"key-10.4103\/1673-5374.360289-22","doi-asserted-by":"crossref","unstructured":"Eysert F, Kinoshita PF, Mary A, Vaillant-Beuchot L, Checler F, Chami M (2020) Molecular dysfunctions of mitochondria-associated membranes (MAMs) in Alzheimer\u2019s disease. Int J Mol Sci 21:9521.","DOI":"10.3390\/ijms21249521"},{"key":"key-10.4103\/1673-5374.360289-23","doi-asserted-by":"crossref","unstructured":"Fenton AR, Jongens TA, Holzbaur ELF (2021) Mitochondrial adaptor TRAK2 activates and functionally links opposing kinesin and dynein motors. Nat Commun 12:4578.","DOI":"10.1038\/s41467-021-24862-7"},{"key":"key-10.4103\/1673-5374.360289-24","doi-asserted-by":"crossref","unstructured":"Franco-Iborra S, Vila M, Perier C (2018) Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson\u2019s disease and Huntington\u2019s disease. Front Neurosci 12:342.","DOI":"10.3389\/fnins.2018.00342"},{"key":"key-10.4103\/1673-5374.360289-25","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez LF, Bevilacqua LE, Naves R (2021) Nanotechnology-based drug delivery strategies to repair the mitochondrial function in neuroinflammatory and neurodegenerative diseases. Pharmaceutics 13:2055.","DOI":"10.3390\/pharmaceutics13122055"},{"key":"key-10.4103\/1673-5374.360289-26","doi-asserted-by":"crossref","unstructured":"Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, Voges O, Rabinovich L, Knebel H, Zientek F, Rullmann M, Sattler B, Patt M, Gerhards T, Strauss M, Kluge A, Brust P, Savola JM, Gordon MF, Geva M, et al. (2021) Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. Eur J Nucl Med Mol Imaging 48:1103-1115.","DOI":"10.1007\/s00259-020-05030-3"},{"key":"key-10.4103\/1673-5374.360289-27","doi-asserted-by":"crossref","unstructured":"Grewal AK, Singh TG, Sharma D, Sharma V, Singh M, Rahman MH, Najda A, Walasek-Janusz M, Kamel M, Albadrani GM, Akhtar MF, Saleem A, Abdel-Daim MM (2021) Mechanistic insights and perspectives involved in neuroprotective action of quercetin. Biomed Pharmacother 140:111729.","DOI":"10.1016\/j.biopha.2021.111729"},{"key":"key-10.4103\/1673-5374.360289-28","doi-asserted-by":"crossref","unstructured":"Guedes-Dias P, de Proen\u00e7a J, Soares TR, Leit\u00e3o-Rocha A, Pinho BR, Duchen MR, Oliveira JMA (2015) HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. Biochim Biophys Acta 1852:2484-2493.","DOI":"10.1016\/j.bbadis.2015.08.012"},{"key":"key-10.4103\/1673-5374.360289-29","doi-asserted-by":"crossref","unstructured":"Hannan MA, Dash R, Sohag AM, Haque N (2020) Neuroprotection against oxidative stress: phytochemicals targeting TrkB signaling and the Nrf2-ARE antioxidant system. Front Mol Neurosci 13:116.","DOI":"10.3389\/fnmol.2020.00116"},{"key":"key-10.4103\/1673-5374.360289-30","doi-asserted-by":"crossref","unstructured":"Hersch SM, Schiffito G, Oakes D, Bredlau A-L, Myers CM, Nahin R, Rosas HD (2017) The CREST-E study of creatine for Huntington disease. Neurology 89:594-601.","DOI":"10.1212\/WNL.0000000000004209"},{"key":"key-10.4103\/1673-5374.360289-31","doi-asserted-by":"crossref","unstructured":"Huntington Study Group TREND-HD Investigators (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582-1589.","DOI":"10.1001\/archneur.65.12.1582"},{"key":"key-10.4103\/1673-5374.360289-32","doi-asserted-by":"crossref","unstructured":"Hurley JH, Young LN (2017) Mechanisms of autophagy initiation. Annu Rev Biochem 86:225-244.","DOI":"10.1146\/annurev-biochem-061516-044820"},{"key":"key-10.4103\/1673-5374.360289-33","doi-asserted-by":"crossref","unstructured":"Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ (1998) 1H NMR spectroscopy studies of Huntington\u2019s disease: correlations with CAG repeat numbers. Neurology 50:1357-1365.","DOI":"10.1212\/WNL.50.5.1357"},{"key":"key-10.4103\/1673-5374.360289-34","doi-asserted-by":"crossref","unstructured":"Jesse S, Bayer H, Alupei MC, Z\u00fcgel M, Mulaw M, Tuorto F, Malmsheimer S, Singh K, Steinacker J, Schumann U, Ludolph AC, Scharffetter-Kochanek K, Witting A, Weydt P, Iben S (2017) Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntington\u2019s disease. Sci Rep 7:8513.","DOI":"10.1038\/s41598-017-09148-7"},{"key":"key-10.4103\/1673-5374.360289-35","doi-asserted-by":"crossref","unstructured":"John A, Kubosumi A, Reddy PH (2020) Mitochondrial microRNAs in aging and neurodegenerative diseases. Cells 9:1345.","DOI":"10.3390\/cells9061345"},{"key":"key-10.4103\/1673-5374.360289-36","doi-asserted-by":"crossref","unstructured":"Johri A, Calingasan NY, Henessey TM, Sharma A, Yang L, Wille E, Chandra A, Beal MF (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 21:1124-1137.","DOI":"10.1093\/hmg\/ddr541"},{"key":"key-10.4103\/1673-5374.360289-37","doi-asserted-by":"crossref","unstructured":"Johri A, Chandra A, Beal MF (2013) PGC-1alpha, mitochondrial dysfunction, and Huntington\u2019s disease. Free Radic Biol Med 62:37-46.","DOI":"10.1016\/j.freeradbiomed.2013.04.016"},{"key":"key-10.4103\/1673-5374.360289-38","doi-asserted-by":"crossref","unstructured":"Julayanont P, Heilman KM, McFarland NR (2020) Early-motor phenotype relates to neuropsychiatric and cognitive disorders in Huntington\u2019s disease. Mov Disord 35:781-788.","DOI":"10.1002\/mds.27980"},{"key":"key-10.4103\/1673-5374.360289-39","doi-asserted-by":"crossref","unstructured":"Jurcau A (2021) Insights into the pathogenesis of neurodegenerative diseases: Focus on mitochondrial dysfunction and oxidative stress. Int J Mol Sci 22:11847.","DOI":"10.3390\/ijms222111847"},{"key":"key-10.4103\/1673-5374.360289-40","doi-asserted-by":"crossref","unstructured":"Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines 10:1432.","DOI":"10.3390\/biomedicines10061432"},{"key":"key-10.4103\/1673-5374.360289-41","doi-asserted-by":"crossref","unstructured":"Jurcau A, Ardelean AI (2022) Oxidative stress in ischemia\/reperfusion injuries following acute ischemic stroke. Biomedicines 10:574.","DOI":"10.3390\/biomedicines10030574"},{"key":"key-10.4103\/1673-5374.360289-42","doi-asserted-by":"crossref","unstructured":"Jurcau A, Ardelean IA (2021) Molecular pathophysiological mechanisms of ischemia\/reperfusion injuries after recanalization therapy for acute ischemic stroke. J Integr Neurosci 20:727-744.","DOI":"10.31083\/j.jin2003078"},{"key":"key-10.4103\/1673-5374.360289-43","doi-asserted-by":"crossref","unstructured":"Jurcau A, Jurcau MC (2022) Therapeutic strategies in Huntington\u2019s disease: from genetic defect to gene therapy. Biomedicines 10:1895.","DOI":"10.3390\/biomedicines10081895"},{"key":"key-10.4103\/1673-5374.360289-44","doi-asserted-by":"crossref","unstructured":"Kalra J (2023) Crosslink between mutations in mitochondrial genes and brain disorders: implications for mitochondrial-targeted therapeutic interventions. Neural Regen Res 18:94-101.","DOI":"10.4103\/1673-5374.343884"},{"key":"key-10.4103\/1673-5374.360289-45","doi-asserted-by":"crossref","unstructured":"Kazlauskaite A, Martinez-Torres RJ, Wilkie S, Kumar A, Peltier J, Gonzalez A, Johnson C, Zhang J, Hope AG, Peggie M, Trost M, van Aalten DM, Alessi DR, Prescott AR, Knebel A, Walden H, Muqit MM (2015) Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation. EMBO Rep 16:939-954.","DOI":"10.15252\/embr.201540352"},{"key":"key-10.4103\/1673-5374.360289-46","doi-asserted-by":"crossref","unstructured":"Khalil B, El Fissi N, Aouane A, Cabirol-Pol MJ, Rival T, Lievens JC (2015) PINK1-induced mitophagy promotes neuroprotection in Huntington\u2019s disease. Cell Death Dis 6:e1617.","DOI":"10.1038\/cddis.2014.581"},{"key":"key-10.4103\/1673-5374.360289-47","doi-asserted-by":"crossref","unstructured":"Kim H, Lee JY, Park KJ, Kim WH, Roh GS (2016) A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci 17:33.","DOI":"10.1186\/s12868-016-0270-y"},{"key":"key-10.4103\/1673-5374.360289-48","doi-asserted-by":"crossref","unstructured":"Labanca F, Ullah H, Khan H, Milella L, Xiao J, Dajic-Stevanovic Z, Jeandet P (2021) Therapeutic and mechanistic effects of curcumin in Huntington\u2019s disease. Curr Neuropharmacol 19:1007-1018.","DOI":"10.2174\/1570159X18666200522201123"},{"key":"key-10.4103\/1673-5374.360289-49","doi-asserted-by":"crossref","unstructured":"Lee M, Ban JJ, Chung JY, Im W, Kim M (2018) Amelioration of Huntington\u2019s disease phenotypes by beta-lapachone is associated with increased Sirt1 expression, CREB phosphorylation and PGC-1\u03b1 deacetylation. PLoS One 13:e0195968.","DOI":"10.1371\/journal.pone.0195968"},{"key":"key-10.4103\/1673-5374.360289-50","doi-asserted-by":"crossref","unstructured":"Liu T, Im W, Mook-Jung I, Kim M (2015) MicroRNA-124 slows down the progression of Huntington\u2019s disease by promoting neurogenesis in the striatum. Neural Regen Res 10:786-791.","DOI":"10.4103\/1673-5374.156978"},{"key":"key-10.4103\/1673-5374.360289-51","doi-asserted-by":"crossref","unstructured":"MacAskill AF, Kittler T (2010) Control of mitochondrial transport and localization in neurons. Trends Cell Biol 20:102-112.","DOI":"10.1016\/j.tcb.2009.11.002"},{"key":"key-10.4103\/1673-5374.360289-52","doi-asserted-by":"crossref","unstructured":"Machiela E, Rudich PD, Traa A, Anglas U, Soo SK, Senchuk MM, Van Raamsdonk JM (2021) Targeting mitochondrial network disorganization is protective in C. elegans models of Huntington\u2019s disease. Aging Dis 12:1753.","DOI":"10.14336\/AD.2021.0404"},{"key":"key-10.4103\/1673-5374.360289-53","doi-asserted-by":"crossref","unstructured":"Mackay JP, Nassrallah WB, Raymond LA (2018) Cause or compensation? Altered neuronal Ca2+ handling in Huntington\u2019s disease. CNS Neurosci Ther 24:301-310.","DOI":"10.1111\/cns.12817"},{"key":"key-10.4103\/1673-5374.360289-54","doi-asserted-by":"crossref","unstructured":"Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD (2016) The role of reactive oxygen species in the pathogenesis of Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease: a mini review. Oxid Med Cell Longev 2016:8590578.","DOI":"10.1155\/2016\/8590578"},{"key":"key-10.4103\/1673-5374.360289-55","doi-asserted-by":"crossref","unstructured":"McGarry A, McDermott M, Kieburtz K, DeBlieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, et al. (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:152-159.","DOI":"10.1212\/WNL.0000000000003478"},{"key":"key-10.4103\/1673-5374.360289-56","doi-asserted-by":"crossref","unstructured":"Mehrotra A, Sood A, Sandhir R (2015) Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington\u2019s disease. Mol Cell Biochem 410:281-292.","DOI":"10.1007\/s11010-015-2561-5"},{"key":"key-10.4103\/1673-5374.360289-57","doi-asserted-by":"crossref","unstructured":"Melkov A, Abdu U (2018) Regulation of long-distance transport of mitochondria along microtubules. Cell Mol Life Sci 75:163-176.","DOI":"10.1007\/s00018-017-2590-1"},{"key":"key-10.4103\/1673-5374.360289-58","doi-asserted-by":"crossref","unstructured":"Monoi H, Futaki S, Kugimiya S, Minataka H, Yoshihara K (2020) Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J 78:2892-2899.","DOI":"10.1016\/S0006-3495(00)76830-5"},{"key":"key-10.4103\/1673-5374.360289-59","doi-asserted-by":"crossref","unstructured":"Moretti D, Tambone S, Cerretani M, Fezzardi P, Missineo A, Sherman LT, Munoz-Sajuan I, Harper S, Dominquez C, Pacifici R, Tomei L, Park L, Bresciani A (2021) NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington\u2019s disease mouse model. Free Radic Biol Med 162:243-254.","DOI":"10.1016\/j.freeradbiomed.2020.10.022"},{"key":"key-10.4103\/1673-5374.360289-60","doi-asserted-by":"crossref","unstructured":"Motawe ZY, Abdelmaboud SS, Cuevas J, Breslin JW (2020) PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation. Int J Biochem Cell Biol.126:105803.","DOI":"10.1016\/j.biocel.2020.105803"},{"key":"key-10.4103\/1673-5374.360289-61","doi-asserted-by":"crossref","unstructured":"Moumn\u00e9 L, Betuing S, Caboche J (2013) Multiple aspects of gene dysregulation in Huntington\u2019s disease. Front Neurol 4:127.","DOI":"10.3389\/fneur.2013.00127"},{"key":"key-10.4103\/1673-5374.360289-62","doi-asserted-by":"crossref","unstructured":"Naia L, Ferreira IL, Ferreiro E, Rego AC (2017) Mitochondrial Ca2+ handling in Huntington\u2019s and Alzheimer\u2019s diseases - role of ER-mitochondria crosstalk. Biochim Biophys Res Commun 483:1096-1077.","DOI":"10.1016\/j.bbrc.2016.07.122"},{"key":"key-10.4103\/1673-5374.360289-63","doi-asserted-by":"crossref","unstructured":"Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, La\u00e7o MN, Hayden MR, Oliveira CR, Rego AC (2017b) Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington\u2019s disease models. Mol Neurobiol 54:5385-5399","DOI":"10.1007\/s12035-016-0048-3"},{"key":"key-10.4103\/1673-5374.360289-64","doi-asserted-by":"crossref","unstructured":"Onyango IG, Bennett JP Jr, Stokin GB (2021) Regulation of neuronal bioenergetics as a therapeutic strategy in neurodegenerative disorders. Neural Regen Res 16:1467-1482.","DOI":"10.4103\/1673-5374.303007"},{"key":"key-10.4103\/1673-5374.360289-65","doi-asserted-by":"crossref","unstructured":"Palikaras K, Tavernarakis N (2014) Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis. Exp Gerontol 56:182-188.","DOI":"10.1016\/j.exger.2014.01.021"},{"key":"key-10.4103\/1673-5374.360289-66","doi-asserted-by":"crossref","unstructured":"Panes JD, Wendt A, Ramirez-Molina O, Castro PA, Fuentealba J (2022) Deciphering the role of PGC-1\u03b1 in neurological disorders: from mitochondrial dysfunction to synaptic failure. Neural Regen Res 17:237-245.","DOI":"10.4103\/1673-5374.317957"},{"key":"key-10.4103\/1673-5374.360289-67","doi-asserted-by":"crossref","unstructured":"Pantiya P, Thonusin C, Chattipakorn N, Chattipakorn SC (2020) Mitochondrial abnormalities in neurodegenerative models and possible interventions: focus on Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease. Mitochondrion 55:14-47.","DOI":"10.1016\/j.mito.2020.08.003"},{"key":"key-10.4103\/1673-5374.360289-68","doi-asserted-by":"crossref","unstructured":"Park A, Oh M, Lee SJ, Oh K-J, Lee E-W, Lee SC, Bae K-H, Han BS, Kim WK (2021) Mitochondrial transplantation as a novel therapeutic strategy for mitochondrial diseases. Int J Mol Sci 22:4793.","DOI":"10.3390\/ijms22094793"},{"key":"key-10.4103\/1673-5374.360289-69","doi-asserted-by":"crossref","unstructured":"Picone P, Porcelli G, Bavisotto CC, Nuzzo D, Galizzi G, Biagio PLS, Bulone D, Di Carlo M (2021) Synaptosomes: new vesicles for neuronal mitochondrial transplantation. J Nanobiotechnol 19:1-15.","DOI":"10.1186\/s12951-020-00748-6"},{"key":"key-10.4103\/1673-5374.360289-70","doi-asserted-by":"crossref","unstructured":"Primeau JO, Armanious GP, Fisher ME, Young HS (2018) The SarcoEndoplasmic Reticulum Calcium ATPase. Subcell Biochem 87:229-258.","DOI":"10.1007\/978-981-10-7757-9_8"},{"key":"key-10.4103\/1673-5374.360289-71","doi-asserted-by":"crossref","unstructured":"Qi X, Qvit N, Su YC, Mochly-Rosen D (2013) A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci 126:789-802.","DOI":"10.1242\/jcs.114439"},{"key":"key-10.4103\/1673-5374.360289-72","doi-asserted-by":"crossref","unstructured":"Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, Kegel KB, Aronin N, DiFiglia M (2004) Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 24:269-281.","DOI":"10.1523\/JNEUROSCI.1409-03.2004"},{"key":"key-10.4103\/1673-5374.360289-73","doi-asserted-by":"crossref","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, Smeeth L (2016) The prevalence of Huntington\u2019s disease. Neuroepidemiology 46:144-153.","DOI":"10.1159\/000443738"},{"key":"key-10.4103\/1673-5374.360289-74","doi-asserted-by":"crossref","unstructured":"Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC (2014) Insulin and IGF-1 improve mitochondrial function in a PI-3K\/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington\u2019s disease knock-in striatal cells. Free Radic Biol Med 74:129-144.","DOI":"10.1016\/j.freeradbiomed.2014.06.023"},{"key":"key-10.4103\/1673-5374.360289-75","doi-asserted-by":"crossref","unstructured":"Roe AJ, Qi X (2018) Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington\u2019s disease. Biochem Biophys Res Commun 496:706-711.","DOI":"10.1016\/j.bbrc.2018.01.114"},{"key":"key-10.4103\/1673-5374.360289-76","doi-asserted-by":"crossref","unstructured":"Rui YN, Xu Z, Patel B, Chen Z, Chen D, Tito A, David G, Sun Y, Stimming EF, Bellen HJ, Cuervo AM, Zhang S (2015) Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol 17:262-275.","DOI":"10.1038\/ncb3101"},{"key":"key-10.4103\/1673-5374.360289-77","doi-asserted-by":"crossref","unstructured":"Sandhir R, Sood A, Mehrotra A, Kamboj SS (2012) N-acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington\u2019s disease. Neurodegen Dis 9:145-157.","DOI":"10.1159\/000334273"},{"key":"key-10.4103\/1673-5374.360289-78","doi-asserted-by":"crossref","unstructured":"Sawant N, Morton H, Kshirsagar S, Reddy AP, Reddy PH (2021) Mitochondrial abnormalities and synaptic damage in Huntington\u2019s disease: a focus on defective mitophagy and mitochondria-targeted therapeutics. Mol Neurobiol 58:6350-6377.","DOI":"10.1007\/s12035-021-02556-x"},{"key":"key-10.4103\/1673-5374.360289-79","doi-asserted-by":"crossref","unstructured":"Schapira AHV, Olanow CW, Greenmayre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: future therapeutic perspectives. Lancet 384:545-555.","DOI":"10.1016\/S0140-6736(14)61010-2"},{"key":"key-10.4103\/1673-5374.360289-80","doi-asserted-by":"crossref","unstructured":"Schrank S, Barrington N, Stutzmann GE (2020) Calcium-handling defects and neurodegenerative disease. Cold Spring Harb Perspect Biol 12:a035212.","DOI":"10.1101\/cshperspect.a035212"},{"key":"key-10.4103\/1673-5374.360289-81","doi-asserted-by":"crossref","unstructured":"Shi X, Zhao M, Fu C, Fu A (2017) Intravenous administration of mitochondria for treating experimental Parkinson\u2019s disease. Mitochondrion 34:91-100.","DOI":"10.1016\/j.mito.2017.02.005"},{"key":"key-10.4103\/1673-5374.360289-82","doi-asserted-by":"crossref","unstructured":"Silva AC, Almeida S, La\u00e7o M, Duarte AI, Domingues J, Oliveira CR, Janu\u00e1rio C, Rego AC (2013) Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington\u2019s disease carriers. Mitochondrion 13:801-809.","DOI":"10.1016\/j.mito.2013.05.006"},{"key":"key-10.4103\/1673-5374.360289-83","doi-asserted-by":"crossref","unstructured":"Stevens M, Oltean S (2019) Modulation of the apoptosis gene Bcl-x function through alternative splicing. Front Genet 10:804.","DOI":"10.3389\/fgene.2019.00804"},{"key":"key-10.4103\/1673-5374.360289-84","doi-asserted-by":"crossref","unstructured":"Sun L, Wei H (2021) Ryanodine receptors: a potential treatment target in various neurodegenerative disease. Cell Mol Neurobiol 41:1613-1624.","DOI":"10.1007\/s10571-020-00936-w"},{"key":"key-10.4103\/1673-5374.360289-85","doi-asserted-by":"crossref","unstructured":"Swerdlow NS, Wilkins HM (2020) Mitophagy and the brain. Int J Mol Sci 21:9661.","DOI":"10.3390\/ijms21249661"},{"key":"key-10.4103\/1673-5374.360289-86","doi-asserted-by":"crossref","unstructured":"The HD iPSC Consortium (2020) Bioenergetic deficits in Huntington\u2019s disease iPSC-derived neural cells and rescue with glycolytic metabolites. Hum Mol Genet 29:1757-1771.","DOI":"10.1093\/hmg\/ddy430"},{"key":"key-10.4103\/1673-5374.360289-87","doi-asserted-by":"crossref","unstructured":"Twelvetrees AE, Lesept F, Holzbaur EL, Kittler JT (2019) The adaptor proteins HAP1a and GRIP1 collaborate to activate the kinesin-1 isoform KIF5C. J Cell Sci 132:215822.","DOI":"10.1242\/jcs.215822"},{"key":"key-10.4103\/1673-5374.360289-88","doi-asserted-by":"crossref","unstructured":"Valencia A, Sapp E, Kimm JS, McClory H, Reeves PB, Alexander J, Ansong KA, Masso N, Frosch MP, Kegel KB, Li X, DiFiglia M. (2013) Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington\u2019s disease. Hum Mol Genet 22:112-1131.","DOI":"10.1093\/hmg\/dds516"},{"key":"key-10.4103\/1673-5374.360289-89","doi-asserted-by":"crossref","unstructured":"Verny C, Bachoud-Levi AC, Durr A, Goizet C, Azulay JP, Simonin C, Tranchant C, Calvas F, Krystkowiak P, Charles P, Youssov K, Scherer C, Prundean A, Olivier A, Reynier P, Saudou F, Maison P, Allain P, von Studnitz E, Bonneau D (2017) A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington\u2019s disease. Mov Disord 32:932-936.","DOI":"10.1002\/mds.27010"},{"key":"key-10.4103\/1673-5374.360289-90","doi-asserted-by":"crossref","unstructured":"Wang S, Shi X, Wei S, Ma D, Oyinlade O, Lv SQ, Ying M, Zhang YA, Claypool SM, Watkins P, Xia S (2018) Kr\u00fcppel-like factor 4 (KLF4) induces mitochondrial fusion and increases spare respiratory capacity of human glioblastoma cells. J Biol Chem 293:6544-6555.","DOI":"10.1074\/jbc.RA117.001323"},{"key":"key-10.4103\/1673-5374.360289-91","doi-asserted-by":"crossref","unstructured":"Wang X, Sirianni A, Pei Z, Cormier K, Smith K, Jiang J, Zhou S, Wang H, Zhao R, Yano H, Kim JE, Li W, Kristal BS, Ferrante RJ, Friedlander RM (2011) The melatonin MT1 receptor axis modulates mutant huntingtin-mediated toxicity. J Neurosci 31:14496-14507.","DOI":"10.1523\/JNEUROSCI.3059-11.2011"},{"key":"key-10.4103\/1673-5374.360289-92","doi-asserted-by":"crossref","unstructured":"Wang Y, Guo X, Ye K, Orth M, Gu Z (2021) Accelerated expansion of pathogenic mitochondrial DNA heteroplasmies in Huntington\u2019s disease. Proc Natl Acad Sci U S A 118:e2014610118.","DOI":"10.1073\/pnas.2014610118"},{"key":"key-10.4103\/1673-5374.360289-93","doi-asserted-by":"crossref","unstructured":"Wong YC, Holzbaur EL (2014) The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. J Neurosci 34:1293-1305.","DOI":"10.1523\/JNEUROSCI.1870-13.2014"},{"key":"key-10.4103\/1673-5374.360289-94","doi-asserted-by":"crossref","unstructured":"Wright DJ, Renoir T, Gray LJ, Hannan AJ (2017) Huntington\u2019s disease: pathogenic mechanisms and therapeutic targets. Neurodegen Dis 15:93-128.","DOI":"10.1007\/978-3-319-57193-5_4"},{"key":"key-10.4103\/1673-5374.360289-95","doi-asserted-by":"crossref","unstructured":"Wu J, Ryskamp D, Birnbaumer L, Bezprozvanny I (2018) Inhibition of the TRPC1-dependent store-operated calcium entry improves synaptic stability and motor performance in a mouse model of Huntington\u2019s disease. J Huntingtons Dis 7:35-50.","DOI":"10.3233\/JHD-170266"},{"key":"key-10.4103\/1673-5374.360289-96","doi-asserted-by":"crossref","unstructured":"Yin X, Manczak M, Reddy PH (2016) Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington\u2019s disease. Hum Mol Genet 25:1739-1753.","DOI":"10.1093\/hmg\/ddw045"},{"key":"key-10.4103\/1673-5374.360289-97","doi-asserted-by":"crossref","unstructured":"Zhu Y, Li C, Tao X, Brazill JM, Park J, Diaz-Perez Z, Zhai RG (2019) NMNAT restores neuronal integrity by neutralizing mutant huntingtin-induced progressive toxicity. Proc Natl Acad Sci U S A 116:19165-19175.","DOI":"10.1073\/pnas.1904563116"},{"key":"key-10.4103\/1673-5374.360289-98","doi-asserted-by":"crossref","unstructured":"Zielonka D (2018) Factors contributing to clinical picture and progression of Huntington\u2019s disease. Neural Regen Res 13:1364-1365.","DOI":"10.4103\/1673-5374.235241"},{"key":"key-10.4103\/1673-5374.360289-99","doi-asserted-by":"crossref","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutic targets in Huntington\u2019s disease. Physiol Rev 90:905-981.","DOI":"10.1152\/physrev.00041.2009"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:37:12Z","timestamp":1787164632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.360289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"alternative-id":["360289"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.360289","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}